News
4 December 2024
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity...
Read more25 October 2024
VIVEbiotech publishes new research paper
We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing...
Read more24 October 2024
Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting
The European Society of Gene and Cell Therapy´s annual congress is in full swing.
Read more10 October 2024
VIVEbiotech participates one more year in the Innovative Therapies Days
VIVEbiotech is participating as a Silver Sponsor in Innovative Therapies Days, a 2-day conference that takes place every year in Besançon, in the R...
Read more8 October 2024
VIVEbiotech participates in Cell & Gene Meeting on the Mesa
As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.
Read more18 September 2024
Q&A in GEN with Natalia Elizalde
Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we...
Read more11 September 2024
VIVEbiotech participates in Advanced Therapies Europe
Natalia Elizalde, Chief Business Development Officer of VIVEbiotech, is participating in Phacilitate's Advanced Therapies Europe conference.
Read more9 September 2024
VIVEbiotech achieves renewal of CIR certification
For the seventh consecutive year and also for the next two, VIVEbiotech has been certified with the CIR – Crédit d´Impôt Recherche certificate.
Read more28 August 2024
New scientific paper in Viruses
VIVEbiotech has published a scientific paper in the journal Viruses
Read more23 August 2024
Enhancing global access to advanced therapies: VIVEbiotech’s role in optimizing production and reducing costs
VIVEbiotech has participated in a second roundtable in Pharma's Almanac entitled “How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?”.
Read moreDestacadas
4 December 2024
25 October 2024
8 October 2024
18 September 2024
11 September 2024
9 September 2024
28 August 2024